Levalox

Levofloxacin, the active ingredient in Levalox, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It is indicated for the treatment of serious bacterial infections in adult patients, including community‑acquired and hospital‑acquired pneumonia, complicated urinary tract infections, complicated intra‑abdominal infections, and skin and soft‑tissue infections.

GNH USA supplies Levalox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide, with a focus on quality and regulatory compliance globally.

Levalox (levofloxacin) is a fluoroquinolone antibiotic used to treat bacterial infections across several organ systems. - Community‑acquired pneumonia: eradicates the causative bacteria, leading to clinical recovery. - Hospital‑acquired pneumonia: provides broad‑spectrum coverage against resistant pathogens. - Complicated urinary tract infections: eliminates Gram‑negative and Gram‑positive organisms in the urinary system. - Complicated intra‑abdominal infections: penetrates abdominal tissues to control polymicrobial infections. - Skin and soft‑tissue infections: resolves infections caused by susceptible Staphylococcus and Streptococcus species.

Levalox may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Tendon rupture: sudden pain and loss of function, especially in the Achilles tendon. - QT interval prolongation: risk of cardiac arrhythmias. - Clostridioides difficile infection: severe colitis with watery diarrhea. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Hepatic failure: jaundice, elevated bilirubin, and liver enzyme abnormalities. - Seizures: especially in patients with pre‑existing CNS disorders.

Use Levalox with caution and monitor patients for specific safety concerns. - Renal function assessment: adjust therapy in patients with impaired clearance. - Tendon health monitoring: advise patients to report tendon pain or swelling promptly. - QT prolongation risk: avoid in patients with known cardiac conduction abnormalities. - Elderly patients: increased susceptibility to adverse events; monitor closely. - Severe hypersensitivity: discontinue immediately if signs of anaphylaxis appear. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levalox can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent fluoroquinolones: additive toxicity and resistance risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened central nervous system stimulation. - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): increased risk of cardiac arrhythmias. - Antacids containing magnesium or aluminum (IV form less affected, but caution with oral switches). - Cytochrome P450 inhibitors (e.g., fluconazole): may raise levofloxacin plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Corticosteroids: elevated risk of tendon rupture. - Diabetic agents: possible alterations in blood glucose control. - Theophylline: increased theophylline concentrations, watch for toxicity. - Cyclosporine: potential increase in cyclosporine levels, monitor renal function.